Kaikki kyselyt tai koulutusmateriaalien paperikopioita koskevat pyynnöt tulee osoittaa Chiesi Pharma AB.

Myyntiluvan haltija:

Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma
Italia

Paikallinen edustaja:

Chiesi Pharma AB
Klara Norra kyrkogata 34
111 22 Stockholm
RUOTSI

Lääketieteelliset tiedot – sähköposti: infonordic@chiesi.com, puhelin: +46 8 753 35 20

Viittauksia

1. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 2016;101:4500–11.

2. Rodriguez AJ, Mastronardi CA, Paz-Filho GJ. New advances in the treatment of generalized lipodystrophy: role of metreleptin. Ther Clin Risk Manag 2015;11:1391–400.

3. Gupta N, Asi N, Farah W, et al. Clinical features and management of non-HIV related lipodystrophy in children: a systematic review. J Clin Endocrinol Metab 2017;102:363–74.

4. Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011;301:E567–84.

5. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 2010;16:310–23.

6. Chiesi Farmaceutici SpA. Myalepta Summary of Product Characteristics.